The Comorbidity of Neurodegenerative and Metabolic Diseases
A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Pharmacology and Drug Metabolism".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 22
Special Issue Editors
Interests: depression; anxiety; epilepsy; neuroscience; preclinical studies
Special Issues, Collections and Topics in MDPI journals
Interests: depression; anxiety; epilepsy; neuroscience; preclinical studies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neurodegenerative diseases represent a broad group of incurable and debilitating illnesses that negatively impact the functioning of neurons in the brain or in the peripheral nervous system. Alzheimer’s disease and other dementias, Parkinson’s disease with Parkinson’s disease-related disorders, Huntington’s disease, or major depressive disorder compromise the conditions that are most frequently diagnosed. Globally, neurodegenerative diseases impact the quality of life of millions of people, affecting not only patients but also their families. Even though the elderly population is a group that is at risk, young adults can also suffer from these medical conditions. There are several different environmental and genetic factors that can promote the development of neurodegenerative diseases; however, sometimes, their cause remains unknown. Metabolic disturbances may affect the development of neurodegenerative diseases, though the molecular mechanisms via which the dysregulation of, for example, glucose or lipid homeostasis exerts a noxious effect on the brain remain poorly understood. Therefore, in our Special Issue, “The Comorbidity of Neurodegenerative and Metabolic Diseases”, we would like to bring together experts working in the field of neurodegenerative diseases and/or metabolic diseases and invite you to present your opinions and suggestions related to the link between these disorders, based on the latest results from pre-clinical research and clinical trials. Review articles exploring associations between the development of neurodegenerative diseases and of metabolic alterations are also welcome.
Prof. Dr. Anna Serefko
Prof. Dr. Aleksandra Szopa
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenerative diseases
- metabolic diseases
- depression
- dementia
- Parkinson’s disease
- Alzheimer’s disease
- Huntington’s disease
- obesity
- diabetes
